Welcome to our dedicated page for NYXOAH S A news (Ticker: NYXH), a resource for investors and traders seeking the latest updates and insights on NYXOAH S A stock.
Nyxoah SA (NYSE: NYXH) is a pioneering health technology company focused on innovative treatments for sleep disordered breathing, particularly Obstructive Sleep Apnea (OSA). This page serves as the definitive source for official updates about their FDA-cleared Genio neurostimulation system, financial developments, and clinical research progress.
Investors and medical professionals will find curated press releases covering regulatory milestones, partnership announcements, and quarterly earnings reports. All content is sourced directly from company filings and verified channels to ensure accuracy.
Key focus areas include updates about international market expansions, clinical trial outcomes for OSA therapies, and technological enhancements to the Genio platform. Bookmark this page to stay informed about Nyxoah's progress in developing patient-centric solutions for chronic sleep conditions.
Nyxoah announced the appointment of Mr. Daniel Wildman as an Independent Director to its Board of Directors on January 9, 2023. Mr. Wildman brings over 40 years of experience in the medical device industry, holding significant positions at major companies like Johnson & Johnson and Boston Scientific. His expertise is expected to bolster Nyxoah's R&D and commercial strategies, particularly for the Genio® hypoglossal nerve stimulation system aimed at treating Obstructive Sleep Apnea (OSA). The appointment is effective immediately, pending shareholder confirmation.
Nyxoah SA has disclosed significant information regarding its share capital and voting rights, as mandated by Belgian law. As of December 29, 2022, the company's share capital stands at EUR 4,440,069.16, with a total of 25,846,279 securities carrying voting rights, comprising all ordinary shares. Additionally, Nyxoah has issued various employee stock option plan (ESOP) warrants, including 700,000 warrants in 2022, allowing subscribers to acquire 4,270,750 total shares. This announcement follows the issuance of new warrants and is essential for transparency with investors.
Nyxoah has filed a $200 million shelf registration statement with the SEC, allowing for the potential sale of various securities. This provides strategic flexibility for future capital access. Additionally, the company has initiated an at-the-market equity offering program, enabling the sale of up to $50 million worth of common shares, with no more than 6 million shares to be issued. The shares will be sold at current market prices on the Nasdaq. This initiative follows Nyxoah's recent progress and approvals in Obstructive Sleep Apnea treatments.
Nyxoah announced its participation in the Piper Sandler 34th Annual Healthcare Conference from November 29 to December 1, 2022, at the Lotte New York Palace hotel. Olivier Taelman, the CEO, will present a corporate update during a fireside chat on December 1 at 12:00 PM ET. A webcast will be available via the Investor Relations website. Nyxoah's lead product, the Genio® system, treats Obstructive Sleep Apnea (OSA) and attained the CE mark in 2019.
Nyxoah reported its financial results for Q3 2022, revealing €182,000 in revenue, a slight decline from €203,000 in the previous year. This drop was largely attributed to a supply disruption affecting €700,000 in orders in Germany. The company completed 110 out of 115 implants for the DREAM U.S. pivotal trial, with 12-month data expected in fall 2023. Operating loss increased to €8.8 million. Nyxoah's cash position stands at €115.4 million, with a monthly cash burn of approximately €3 million.
Nyxoah announced the resignation of Raymond Cohen from its board of directors, effective October 18, 2022. This change occurs in a company focused on innovative solutions for treating Obstructive Sleep Apnea (OSA), highlighting the need for strong leadership amid ongoing product developments. The company’s Genio® system received CE Mark approval in 2019 and is currently undergoing the DREAM IDE pivotal study for FDA approval. This management shift may impact Nyxoah’s strategic direction as it continues to expand its market presence.
Nyxoah will participate in the Jefferies London Healthcare Conference from November 15-17, 2022. The event will be held at The Waldorf Hilton, London. CEO Olivier Taelman will provide a corporate update during a fireside chat on November 17 at 10:25am GMT. A webcast will be available on the Company's Investor Relations page. Nyxoah specializes in treating Obstructive Sleep Apnea with its lead product, the Genio® system, which received European CE Mark approval in 2019.
Nyxoah has announced the release date for its third quarter financial results, scheduled for November 8, 2022, after market close. The medical technology company specializes in innovative solutions for Obstructive Sleep Apnea (OSA). The company’s management will host a conference call at 10:30 PM CET / 4:30 PM ET to discuss the results. Interested investors can register for the call online. Nyxoah is known for its Genio® system, which has received CE mark approval for treating OSA and is currently conducting studies for FDA approval.
Nyxoah SA disclosed new share capital information in a regulatory announcement dated September 30, 2022. The company reported a total share capital of EUR 4,440,069.16 and indicated that there are 25,846,279 securities carrying voting rights, consisting entirely of ordinary shares. Furthermore, it outlined the number of subscription rights for various Employee Stock Option Plans (ESOP) dating from 2016 to 2021, which entitle holders to subscribe for a total of 1,916,625 additional securities.
Nyxoah, a medical technology company specializing in solutions for Obstructive Sleep Apnea (OSA), will participate in the 17th Annual Wells Fargo Securities Healthcare Conference from September 7-9, 2022, in Everett, MA. Management will conduct one-on-one meetings with investors on September 9. The announcement comes as Nyxoah continues to advance its Genio® system, a revolutionary treatment for OSA. With CE Mark approval since 2019 and ongoing studies for FDA approval, Nyxoah aims to improve patient outcomes and expand its market presence.
FAQ
What is the current stock price of NYXOAH S A (NYXH)?
What is the market cap of NYXOAH S A (NYXH)?
